8.23
price down icon1.79%   -0.15
after-market Dopo l'orario di chiusura: 8.16 -0.07 -0.85%
loading

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

pulisher
08:00 AM

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe

08:00 AM
pulisher
08:00 AM

Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan

08:00 AM
pulisher
Mar 27, 2025

Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR

Mar 27, 2025
pulisher
Mar 25, 2025

Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st

Mar 25, 2025
pulisher
Mar 21, 2025

Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com

Mar 21, 2025
pulisher
Mar 19, 2025

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha

Mar 19, 2025
pulisher
Mar 17, 2025

Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider

Mar 17, 2025
pulisher
Mar 12, 2025

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Amneal at Barclays Healthcare Conference: Growth and Innovation Insights - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace

Mar 11, 2025
pulisher
Mar 10, 2025

Amneal to Participate at Upcoming Investor Conference - WICZ

Mar 10, 2025
pulisher
Mar 10, 2025

Amneal Pharmaceuticals CEO Set for Key Presentation at Barclays Healthcare Conference - Stock Titan

Mar 10, 2025
pulisher
Mar 08, 2025

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 08, 2025

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 07, 2025

Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR - GlobeNewswire Inc.

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales - Insights

Mar 07, 2025
pulisher
Mar 07, 2025

Principal Financial Group Inc. Purchases 8,213 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Amneal Pharmaceuticals director Patel sells $712,000 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Amneal Pharmaceuticals director Patel sells $712,000 in stock - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Amneal Receives FDA Approval for Lenalidomide - Clinical Oncology News

Mar 06, 2025
pulisher
Mar 06, 2025

Amneal Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - The Globe and Mail

Mar 05, 2025
pulisher
Mar 05, 2025

US Denosumab Race Remains Busy As Amneal And mAbxience See Filing Accepted - insights.citeline.com

Mar 05, 2025
pulisher
Mar 04, 2025

Handelsbanken Fonder AB Acquires Shares of 39,000 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Purchases 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Given New $11.00 Price Target at Barclays - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - BioSpace

Mar 03, 2025
pulisher
Mar 03, 2025

Full Fed. Circ. Won't Take On Teva's Orange Book Appeal - Law360

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers - MSN

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal, mAbxience's Biologics Licensing Application for Denosumab Biosimilars Accepted for Review by FDA - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal seeks FDA nod for bone therapy biosimilars By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal seeks FDA nod for bone therapy biosimilars - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

New York State Common Retirement Fund Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $10.60 - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

JP Morgan Upgrades Amneal Pharmaceuticals (AMRX) - MSN

Mar 02, 2025
$32.53
price down icon 1.48%
$97.93
price up icon 0.34%
$8.60
price down icon 1.26%
$107.00
price down icon 3.25%
$306.88
price down icon 0.45%
$131.87
price down icon 0.04%
Capitalizzazione:     |  Volume (24 ore):